Article
AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.
Blood - 27 May 2010
Lin Tzu-Yin, Fenger Joelle, Murahari Sridhar, Bear Misty D, Kulp Samuel K, Wang Dasheng, Chen Ching-Shih, Kisseberth William C, London Cheryl A
Abstract excerpt
Histone hypoacetylation occurs in many cancers and inhibition of histone deacetylation is a promising approach to modulate these epigenetic changes. Our laboratory previously demonstrated that the histone deacetylase inhibitors (HDACis) vorinostat and AR-42 reduced the viability of a canine malignant mast cell line. The purpose of this study was to further investigate the mechanisms of pan-HDAC inhibition in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.